Fecal Microbiota Transplantation for C Diff Infection

Status Recruiting

Clinical Trial Summary

The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI). It has been shown that good bacteria (like that found in the stool from a healthy donor) attack Clostridium difficile in multiple ways: they make substances that kill Clostridium difficile - and they attach to the surface of the colon lining, which prevents the Clostridium difficile toxin (poison) from attaching. FMT involves infusing a mixture of saline and stool from a healthy donor into the bowel of the patient with CDI during a colonoscopy. The method used to deliver the FMT will depend on individual characteristics of the subject and is at the discretion of the treating physician. FMT may be administered by the following methods. - Colonoscopy: This method allows full endoscopic examination of the colon and exclusion of comorbid conditions (such as IBD, malignancy or microscopic colitis) which may have an impact on subject's treatment or response to therapy. - Sigmoidoscopy: This method still allows infusion of the stool into a more proximal segment of the colon than an enema, but may not require sedation. This method may be beneficial in subjects who are elderly or multiparous and who may have difficulty retaining the material when given as enema. Sigmoidoscopic administration eliminates the additional risks associated with colonoscopy in subjects who may not have a clear indication for colonoscopy. - Retention enema: This method may be preferable in younger subjects who have already had recent endoscopic evaluation, in subjects who prefer not to undergo endoscopy or in subjects with significant co morbidities and may not tolerate endoscopy. The physician will administer 300-500 mL of the fecal suspension in aliquots of 60 mL, through the colonoscope or sigmoidoscope or 150 mL via retention enema. In cases of colonoscopic delivery, the material will be delivered to the most proximal point of insertion. The subject is encouraged to retain stool for as long as possible.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01905709
Study type	Interventional
Source	Englewood Hospital and Medical Center
Contact	Marc Fiorillo, MD
Phone	201-945-6564
Email	fiorillomd@gmail.com
Status	Recruiting
Phase	N/A
Start date	July 2013
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02214771` - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients	N/A
Withdrawn	`NCT01552668` - Fidaxomicin to Prevent Clostridium Difficile Colonization	Phase 4
Recruiting	`NCT03325855` - Fecal Microbiota Transplant National Registry
Not yet recruiting	`NCT03586206` - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended	`NCT03350711` - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn	`NCT03643887` - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients	Phase 2
Terminated	`NCT04000555` - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)	Phase 4
Terminated	`NCT03065374` - Treatment for Clostridium-difficile Infection With IMM529	Phase 1/Phase 2
Completed	`NCT03710694` - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)	N/A
Completed	`NCT02865616` - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)	Phase 1
Recruiting	`NCT04940468` - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology	N/A
Completed	`NCT02589847` - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	Phase 2
Not yet recruiting	`NCT01942447` - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis	N/A
Active, not recruiting	`NCT02086916` - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection	N/A
Completed	`NCT01230957` - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults	Phase 2
Completed	`NCT01241552` - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	Phase 3
Not yet recruiting	`NCT04567134` - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed	`NCT04075422` - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting	`NCT03712722` - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting	`NCT05192148` - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile	N/A